---
figid: PMC6726851__Dtsch_Arztebl_Int-116_0497_002
figtitle: Inhibition of the MAPK(RAS-RAF-MEK-ERK) signaling pathway by BRAF inhibitors
  and MEK inhibitorsMAPK, mitogen-activated protein kinase; RTK, receptor-tyrosine-kinase
organisms:
- NA
pmcid: PMC6726851
filename: Dtsch_Arztebl_Int-116_0497_002.jpg
figlink: /pmc/articles/PMC6726851/figure/F2/
number: F2
caption: Inhibition of the MAPK(RAS-RAF-MEK-ERK) signaling pathway by BRAF inhibitors
  and MEK inhibitorsMAPK, mitogen-activated protein kinase; RTK, receptor-tyrosine-kinase
papertitle: The Systemic Treatment of Melanoma.
reftext: Patrick Terheyden, et al. Dtsch Arztebl Int. 2019 Jul;116(29-30):497-504.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8612274
figid_alias: PMC6726851__F2
figtype: Figure
organisms_ner:
- NA
redirect_from: /figures/PMC6726851__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6726851__Dtsch_Arztebl_Int-116_0497_002.html
  '@type': Dataset
  description: Inhibition of the MAPK(RAS-RAF-MEK-ERK) signaling pathway by BRAF inhibitors
    and MEK inhibitorsMAPK, mitogen-activated protein kinase; RTK, receptor-tyrosine-kinase
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Vemurafenib
  - Dabrafenib
  - Encorafenib
  - Cobimetinib
  - Trametinib
  - Binimetinib
  - Melanoma
---
